RecruitingRecruiting
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
NCT07803744 · Eli Lilly and Company
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
About this study
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.
Participation in this study will last about 8 weeks, including screening and follow-up.
Eligibility criteria
Inclusion Criteria:
* Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
* Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
* Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening
Exclusion Criteria:
* Participants who have a known clinically significant gastric emptying abnormality
* Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
* Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists
Study design
Enrollment target: 18 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-09-11
Estimated completion: 2026-12
Last updated: 2026-09-23
Interventions
Drug: TirzepatideDrug: AcetaminophenDrug: Placebo
Primary outcomes
- • Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen (Predose on Day 1 through 36 hours post dose)
- • PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Acetaminophen (Predose on Day 1 through 36 hours post dose)
- • PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen (Predose on Day 1 through 36 hours post dose)
Sponsor
Eli Lilly and Company · industry
Contacts & investigators
ContactTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · contact · LillyTrials@Lilly.com · 1-317-615-4559
ContactPhysicians interested in becoming principal investigators please contact · contact · clinical_inquiry_hub@lilly.com
InvestigatorCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · study_director, Eli Lilly and Company
All locations (1)
Clinical Pharmacology of MiamiRecruiting
Miami, Florida, United States